DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Analysts

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $48.50.

DBVT has been the topic of several research analyst reports. Citizens Jmp lifted their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 30th. Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, June 29th. HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Finally, Guggenheim reissued a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a research report on Monday, May 4th.

DBV Technologies Stock Up 4.5%

Shares of DBVT stock traded up $0.70 on Tuesday, reaching $16.32. 104,139 shares of the stock were exchanged, compared to its average volume of 296,459. DBV Technologies has a 1-year low of $8.51 and a 1-year high of $26.18. The stock has a market cap of $966.01 million, a P/E ratio of -3.66 and a beta of -0.95. The firm has a 50 day moving average of $17.89 and a two-hundred day moving average of $19.75.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). The firm had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. On average, equities research analysts predict that DBV Technologies will post -0.38 EPS for the current fiscal year.

Institutional Trading of DBV Technologies

Large investors have recently added to or reduced their stakes in the stock. UBS Group AG raised its holdings in shares of DBV Technologies by 165,347.3% during the 4th quarter. UBS Group AG now owns 244,862 shares of the company’s stock valued at $4,694,000 after buying an additional 244,714 shares during the period. DLD Asset Management LP purchased a new position in DBV Technologies in the 3rd quarter worth approximately $250,000. Polymer Capital Management HK LTD purchased a new position in DBV Technologies in the 4th quarter worth approximately $1,236,000. AdvisorShares Investments LLC acquired a new stake in DBV Technologies in the first quarter valued at approximately $1,052,000. Finally, Vivo Capital LLC grew its position in DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after acquiring an additional 205,943 shares in the last quarter. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.